Evidence map›Paper›PMID 37965465›Full record

ArticleFrontiers in oncology2023

Histopathological growth pattern of liver metastases as an independent marker of metastatic behavior in different primary cancers.

Ali Bohlok, François Richard, Valerio Lucidi, Antoine El Asmar, Pieter Demetter, Ligia Craciun, Denis Larsimont, Alain Hendlisz, Jean Luc Van Laethem, Luc Dirix and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Ali BohlokSurgical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
François RichardLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.
Valerio LucidiAbdominal Surgery, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Antoine El AsmarSurgical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Pieter DemetterPathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Ligia CraciunPathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Denis LarsimontPathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Alain HendliszDigestive Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Jean Luc Van LaethemHepatogastroenterology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Luc DirixTranslational Cancer Research Unit, Gasthuiszusters Antwerp Hospitals and University of Antwerp, Antwerp, Belgium.
Christine DesmedtLaboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.
Peter Vermeulen *Translational Cancer Research Unit, Gasthuiszusters Antwerp Hospitals and University of Antwerp, Antwerp, Belgium.
Vincent Donckier *Surgical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Institut Jules Bordet · BEUniversité Libre de Bruxelles · BEErasmus Hospital · BEKU Leuven · BEAntwerp University Hospital · BEUniversity of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surgical resection can lead to prolonged survival in patients with isolated liver metastases (LM) from various primary cancers. However, there are currently no validated predictive markers to discriminate between these oligo/argometastatic patients, who will benefit from surgery, and those with diffuse metastatic behavior in whom surgery will be futile. To evaluate whether the tumor microenvironment, or histopathological growth pattern (HGP), of LM reflects the type of metastatic progression independently of the origin of the primary cancer, we analyzed a combined series of patients who underwent surgery for colorectal LM (N=263) or non-colorectal LM (N=66). HGPs of LM were scored in each patient to distinguish between desmoplastic HGP (all LM showing a complete encapsulated pattern) and non-desmoplastic HGP (at least one LM with some infiltrating-replacement component). In the entire series, 5-year overall and progression-free survival were, 44.5% and 15.5%, respectively, with no significant differences between colorectal and non-colorectal LM. In patients with desmoplastic HGP, 5-year overall and progression-free survival were 57% and 32%, respectively, as compared to 41% and 12%, respectively, in patients with non-desmoplastic-HGP (p=0.03 and 0.005). Irrespective of cancer origin and compared to traditional risk factors, desmoplastic HGP was the most significant predictor for better post-operative overall survival (adjusted HR: 0.62; 95% CI: [0.49-0.97]; p=0.035) and progression-free survival (adjusted HR: 0.61; 95% CI: [0.42-0.87], p=0.006). This suggests that the HGP of LM may represent an accurate marker that reflects the mode of metastatic behavior, independently of primary cancer type.

Indexed as

histopathological growth patternlivermarkermetastasesprognostic

Identifiers

PMID37965465
PMCPMC10641477
OpenAlexW4388189306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.